Results 161 to 170 of about 22,657 (185)

Anti-CD74 IgA as a potential biomarker in axial spondyloarthritis: diagnostic utility and clinical implications. [PDF]

Clin Rheumatol
Ammar GEM, Eldeeb AE, Mourad HA, Tabra SA.   +3 more
europepmc   +1 more source

The Pathophysiological Significance of Dual Inhibition of IL-17A and IL-17F in Psoriatic Arthritis and Axial Spondyloarthritis. [PDF]

Mediterr J Rheumatol
Katsouli O, Lainis V, Goules AV, Vlachoyiannopoulos PG.   +3 more
europepmc   +1 more source

Diagnostic Utility and Economic Impact of a Sequential MRI Protocol in Axial Spondyloarthritis: A Retrospective Cohort Study. [PDF]

Cureus
Yuan-Doré JSJ, Kumar S, Kostanjsek L, Tahir SA, Bamford S, Tilden W, Tahir H.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
Filip E Van Den Bosch, Denis Poddubnyy, Walter P Maksymowych   +2 more
exaly  

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis

Lancet, The, 2022
Jean W Liew, Maureen Dubreuil
exaly  

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Lancet, The, 2020
Atul Deodhar, Mrcp, Désirée M Van Der Heijde, Tae-Hwan Kim   +2 more
exaly